Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for Humacyte in a research report issued on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.40) for the year, up from their previous forecast of ($1.41). Cantor Fitzgerald currently has a "Overweight" rating and a $13.00 target price on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share.
Several other research analysts have also recently weighed in on HUMA. Benchmark raised their target price on Humacyte from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Monday, December 23rd. HC Wainwright restated a "buy" rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a "neutral" rating in a report on Friday, October 18th. D. Boral Capital restated a "buy" rating and set a $25.00 target price on shares of Humacyte in a report on Monday. Finally, TD Cowen restated a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Humacyte has a consensus rating of "Buy" and a consensus price target of $13.71.
Get Our Latest Stock Report on HUMA
Humacyte Stock Performance
Shares of HUMA stock traded down $0.07 during mid-day trading on Friday, hitting $4.41. 2,264,931 shares of the stock traded hands, compared to its average volume of 3,264,841. Humacyte has a twelve month low of $2.53 and a twelve month high of $9.97. The company's 50-day simple moving average is $4.58 and its 200-day simple moving average is $5.66. The firm has a market cap of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32.
Insider Transactions at Humacyte
In other news, CEO Laura E. Niklason sold 811,172 shares of the firm's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now owns 2,419,712 shares of the company's stock, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 over the last ninety days. Corporate insiders own 11.20% of the company's stock.
Institutional Trading of Humacyte
A number of hedge funds have recently made changes to their positions in the stock. Private Advisor Group LLC increased its stake in Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company's stock valued at $2,030,000 after buying an additional 6,510 shares during the period. SG Americas Securities LLC grew its holdings in shares of Humacyte by 22.0% during the 4th quarter. SG Americas Securities LLC now owns 39,143 shares of the company's stock valued at $198,000 after acquiring an additional 7,069 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Humacyte by 32.5% in the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company's stock worth $168,000 after acquiring an additional 8,557 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Humacyte by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company's stock worth $125,000 after acquiring an additional 8,965 shares in the last quarter. Finally, Brookstone Capital Management bought a new stake in shares of Humacyte in the 4th quarter valued at approximately $56,000. 44.71% of the stock is owned by hedge funds and other institutional investors.
About Humacyte
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
